This page shows the latest Ganymed Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
This is the second major deal for Astellas in a few months, following a $1.4bn acquisition of Germany's Ganymed Pharmaceuticals that gave it a gastric cancer antibody (IMAB362) in
Astellas has agreed to pay 422m upfront to buy Ganymed Pharmaceuticals, a German biopharma company specialising in antibody-based cancer drugs. ... If all goes according to plan, Ganymed's shareholders could pick up an additional 860m in milestones,
The Struengmanns already hold stakes in German biotechnology companies including 4SC and Ganymed Pharmaceuticals, which is developing monoclonal antibody therapeutics to fight solid cancer tumours.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...